Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

In those being screened for hereditary breast and ovarian cancer syndrome, use of a video tool improved the duration of physician-led genetic counseling.

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.

Data from the phase 3 ASTRUM-005 trial support the MHRA’s approval of serplulimab for patients with extensive-stage small cell lung cancer.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.